Open AccessPB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL‐760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR OTHER NON‐HODGKIN LYMPHOMA
Author(s) -
Kahl B.,
Cohen J.,
Pillai R.,
Jayaprakash V.,
Wang C.,
HahkaKemppinen M.,
Kania M.,
Zinzani P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850372.60201.c7
Subject(s) - chronic lymphocytic leukemia , tolerability , medicine , ibrutinib , bruton's tyrosine kinase , lymphoma , pharmacology , oncology , pharmacokinetics , leukemia , pharmacodynamics , adverse effect , tyrosine kinase , receptor